Reimagining Medicine Q2 2023 Results

Company overview Financial review Innovation: Pipeline overview Financial performance Cardiovascular Immunology BeovuⓇ - VEGF Inhibitor NCT04278417 CONDOR (CRTH258D2301) Indication Diabetic retinopathy Phase 3 Change from Baseline in BCVA Phase Patients 694 Primary Outcome Measures Arms Conclusions Intervention Arm 1: RTH258 (brolucizumab) 6 mg/50uL Arm 2: Panretinal photocoagulation laser initial treatment followed with additional PRP treatment as needed Patients with proliferative diabetic retinopathy Target Patients Readout Milestone(s) 2024 Publication TBD Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 80 Investor Relations | Q2 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation